活跃期停用缩宫素对新生儿发病率的影响:一项开放标签、多中心、随机试验
STOPOXY为法国21家产科单位开展的多中心、随机、开放标签、优效性试验,纳入宫口<4 cm时已接受缩宫素的产妇,1:1随机分为不连续缩宫素组(宫口≥6 cm后停止输注)与持续缩宫素组(持续至分娩)。主要终点为新生儿发病率复合变量(脐动脉pH<7.10、碱剩余>10 mmol/L、脐动脉乳酸>7 mmol/L、5分钟Apgar评分<7或入住新生儿重症监护病房)。改良意向性分析纳入2170例,不连续组发生率9.6%(102/1067,95%CI 7.9–11.5),持续组9.2%(101/1103,95%CI 7.6–11.0),绝对差0.4%(95%CI -2.1至2.9),相对危险度1.0(95%CI 0.8–1.4)。两组不良事件无临床显著差异,作者结论为活跃期停用缩宫素未在临床或统计学上显著降低新生儿发病率。
要点
- 宫口<4 cm时已用缩宫素的产妇,宫口≥6 cm后停用缩宫素,新生儿发病率9.6%(102/1067)vs 持续组9.2%(101/1103),绝对差0.4%(95%CI -2.1至2.9)。
- 相对危险度1.0(95%CI 0.8–1.4),停用缩宫素未在统计学上显著降低新生儿发病率。
- 主要终点为复合变量:脐动脉pH<7.10、碱剩余>10 mmol/L、脐动脉乳酸>7 mmol/L、5分钟Apgar评分<7或入住新生儿重症监护病房。
- 两组不良事件无临床显著差异。
- 作者结论:早期产程已用缩宫素者,进入活跃期停用缩宫素不能临床或统计学显著降低新生儿发病率。
适用人群与场景
- 法国21家产科单位中,宫口<4 cm时已接受缩宫素的产妇,随机分组时已进入活跃期(宫口≥6 cm)者纳入改良意向性分析。
- 排除随机后撤回知情同意或判定不符合条件者。
诊断标准与关键阈值
- 主要终点新生儿发病率复合变量定义:脐动脉pH<7.10、碱剩余>10 mmol/L、脐动脉乳酸>7 mmol/L、5分钟Apgar评分<7或入住新生儿重症监护病房,满足任一即计入。
- 干预启动阈值:宫口扩张≥6 cm时停止缩宫素输注(不连续组)。
处置流程与药物剂量
- 不连续缩宫素组:宫口扩张≥6 cm后停止缩宫素输注。
- 持续缩宫素组:缩宫素持续给药至分娩。
- 随机化按中心和产次分层。
研究设计与关键结果
- STOPOXY为多中心、随机、开放标签、对照、优效性试验,2020年1月13日至2022年1月24日随机2459例,2170例纳入改良意向性分析。
- 主要终点:不连续缩宫素组102/1067(9.6%,95%CI 7.9–11.5)vs 持续缩宫素组101/1103(9.2%,95%CI 7.6–11.0),绝对差0.4%(95%CI -2.1至2.9),相对危险度1.0(95%CI 0.8–1.4)。
- 两组不良事件无临床显著差异。
证据类型、等级与局限
- 证据类型:多中心、随机、开放标签、对照、优效性试验(STOPOXY,NCT03991091)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于宫口<4 cm时已开始缩宫素的产妇,进入活跃期(宫口≥6 cm)后停用缩宫素与持续使用相比,新生儿发病率无统计学显著差异,作者结论为停用缩宫素未临床或统计学显著降低新生儿发病率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Oxytocin is effective in reducing labour duration but can be associated with fetal and maternal complications that could potentially be reduced by discontinuing the treatment during labour. We aimed to assess the impact of discontinuing oxytocin during active labour on neonatal morbidity.
METHODS: STOPOXY was a multicentre, randomised, open-label, controlled, superiority trial conducted in 21 maternity units in France. Participants who received oxytocin before 4 cm dilation were randomly assigned 1:1 to either discontinuous oxytocin (oxytocin infusion stopped beyond a cervical dilation equal to or greater than 6 cm) or continuous oxytocin (administration of oxytocin continued until delivery). Randomisation was stratified by centre and parity. The primary outcome, neonatal morbidity, was assessed at birth using a composite variable defined by an umbilical arterial pH at birth less than 7·10, a base excess greater than 10 mmol/L, umbilical arterial lactates greater than 7 mmol/L, a 5-min Apgar score less than 7, or admission to the neonatal intensive care unit. Efficacy and safety was assessed in participants who were randomly assigned (excluding those who withdrew consent or were deemed ineligible after randomisation) and had reached a cervical dilation of at least 6 cm. This trial is registered with ClinicalTrials.gov, NCT03991091.
FINDINGS: Of 2459 participants randomly assigned between Jan 13, 2020, and Jan 24, 2022, 2170 were eligible to receive the intervention and were included in the final modified intention-to-treat analysis. The primary outcome occurred for 102 (9·6%) of 1067 participants (95% CI 7·9 to 11·5) in the discontinuous oxytocin group and for 101 (9·2%) of 1103 participants (7·6 to 11·0) in the continuous oxytocin group; absolute difference 0·4% (95% CI -2·1 to 2·9); relative risk 1·0 (95% CI 0·8 to 1·4). There were no clinically significant differences in adverse events between the two groups of the safety population.
INTERPRETATION: Among participants receiving oxytocin in early labour, discontinuing oxytocin when the active phase is reached does not clinically or statistically significantly reduce neonatal morbidity compared with continuous oxytocin.
FUNDING: French Ministry of Health and the Département de la Recherche Clinique et du Développement de l'Assistance Publique-Hôpitaux de Paris.
参考来源
- Girault A, Sentilhes L, Desbrière R, et al. Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial. Lancet. 2023. PMID: 37952548. doi:10.1016/S0140-6736(23)01803-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。